## PRIOR AUTHORIZATION REQUEST FORM EOC ID: Medicare Part D- Cyclobenzaprine and Metaxalone

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

	Prescriber Name: Supervising Physician:	
Patient Name:		
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
g	4400	
Q1. Which medication is being requested?		
☐ Cyclobenzaprine ☐ Metaxalone	☐ Other	
Q2. What indication will the requested medication be us	ed for?	
☐ Muscle Spasm		
☐ Acute, painful musculoskeletal conditions		
☐ Spasticity		
☐ Fibromyalgia		
☐ Other (Please explain)		
Q3. Please provide ICD code(s) for indication being trea	ated	
der i isase previde res sede(e) for indication being tree		
Q4. If requested indication is fibromyalgia, please indica	ate all medications previou	usly tried.
☐ Paroxetine		
☐ Fluoxetine		

## PRIOR AUTHORIZATION REQUEST FORM EOC ID: Medicare Part D- Cyclobenzaprine and Metaxalone

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

megible may delay the review process.		
	Prescriber Name:	
Patient Name:	Supervising Physician:	
☐ Duloxetine		
☐ Gabapentin		
Lyrica		
Savella		
Other (please explain)		
•	as a high-risk medication when used in patients age 65 and s of treatment prior to initiating therapy. Ongoing monitoring for uld be considered for continuation of therapy as the risks	
Q6. Additional comments:		
Prescriber Signature	Date	

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document